Novartis AG
NVSHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 9, 2026
Scan Results
Daily timeframeNovartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The $261.73B market capitalization puts NVS squarely in mega-cap range for its industry. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
Market Cap
$261.73B
Beta
0.49
P/E (TTM)
20.80
P/E (Fwd)
14.04
EPS (TTM)
$6.62
EPS (Fwd)
$9.81
ROE
30.3%
ROA
10.3%
Cash
$7.62B
Total Debt
$49.01B
Free CF
$11.90B
52W Change
26.4%
Annual Financials
Cash vs Debt
Where NVS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NVS finished 6.37% above its 150-day moving average ($152.73) and 9.96% above its 200-day moving average ($147.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVS overbought or oversold?
At the September 3, 2026 close, NVS's RSI(14) was 64.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $7.62B in cash, though total debt stands at $49.01B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $11.90B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 30.3% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.2% further supports the picture of efficient asset utilization. Revenue has grown from $43.46B (2022) to $56.67B (2025), reflecting a 30% increase over the period.
NVS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Novartis AG carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Novartis AG's trajectory.